Section 1: At a Glance
₹731.2 Cr revenue. ₹52.4 Cr net profit. ₹85.92 EPS. A P/E of 11.7x. Empire Industries — the 126-year-old Mumbai conglomerate — just posted numbers that suggest a company in equilibrium. Not growth. Not decline. Just flat, steady, respectable equilibrium. The kind of equilibrium that makes professional investors yawn and promoters quietly issue ₹50 per share in special dividends.
But before you scroll past: there’s something genuinely odd here. A company that once dominated container glass, now diversified across glass, frozen foods, machine tools, real estate, and office leasing, shouldn’t be this quiet. The quarterly results show a last quarter that finally woke up—₹195 Cr in sales, ₹19 Cr in profit—but the full-year tells a different story: growth that barely outpaced inflation, margins that wobble, and a balance sheet that looks less like a growth company and more like a family office managing legacy assets.
The stock trades at 11.7x earnings on a 15.6% ROE. The sector median is 15.2x on an 11.9% ROE. On paper, Empire is cheaper and more profitable. In practice, it trades like a value trap. The question isn’t whether the numbers are accurate. They are. The question is whether this business can ever matter again.
Wisdom drop: A company’s cheapness relative to the sector is often a price paid for invisibility, not opportunity. Empire’s modest valuation reflects not underappreciation but genuine lack of momentum.
Section 2: Introduction
Empire Industries Limited was founded in 1900—the same year Gillette invented the safety razor and Planck introduced quantum theory. For most of the 20th century, it was a name that mattered in Mumbai’s industrial circles: glass bottles for pharma, machine tools for factories, a sprawling real estate play. The Malhotra family, which controls 72.6% of the company, has kept it intact through independence, globalisation, and the rise of private capital.
Today, it survives as a holding company disguised as an operating business. Glass manufacturing still exists. Food trading still happens. Leasing of office space in Lower Parel and Vikhroli continues. But momentum? That left sometime in the previous decade.
FY26 was a year of consolidation, not transformation. Revenues grew 8%, net profit actually declined 1.5% (to ₹52.4 Cr from ₹54 Cr in FY25), yet somehow the dividend recommendation doubled. The dividend story — ₹50 per share, comprising ₹25 final and ₹25 special — is the loudest message management sent all year. Cash-rich, growth-quiet.
Section 3: Business Model: WTF Do They Even Do?
Empire’s business model reads like a company in slow-motion fragmentation. The glass division manufactures 1.9 million amber bottles daily — sold mostly to beverage makers (60%) and pharmaceutical companies (40%). The change in customer mix is deliberate: beverages carry better margins. High capacity utilisation at 95% masks the fact that utilisation, once at 100%, has stayed soft. The glass division contributes ~35% of revenue.
Trading and indenting — a euphemism for importing machine tools and frozen foods — accounts for ~43% of revenue. Frozen foods have seen 20% growth (per the CARE rating), but margins are thin and forex volatility is a constant headache. Machine tools? Government capex cycles rule its fate.
Then there’s the real estate division. The company owns 35 acres in Ambernath, mostly undeveloped. Three residential phases are under construction (20-45% complete), with 81% of units sold. The division is currently loss-making, but management banks on the upcoming Chikoli railway station to drive future appreciation. A classic real estate play: customer-funded, execution-dependent, long-duration risk.
Finally, the leave-and-license leasing business. Two office properties in Lower Parel and Vikhroli, both now fully occupied after previous slack. ₹11 Cr of annual rental income. Sticky, low-growth, but profitable.
The verdict: This is not a business. It’s a portfolio. The question is whether any of these assets justify the ₹604 Cr market cap, or whether that’s just the cost of holding them until they grow up — or sell.
Section 4: Financials Overview
Figures are consolidated, in ₹ crore.
| Metric | Q4 FY26 | YoY | FY26 | FY25 | Change |
|---|---|---|---|---|---|
| Revenue | 195.4 | +4.8% | 731.2 | 677.0 | +8.0% |
| Operating Profit | 32.9 | +159% | 87 | 70 | +24.3% |
| Net Profit | 19.2 | +332% | 52.4 | 54.0 | -1.5% |
| EPS (₹) | 31.98 | — | 85.92 | 89.94 | -4.5% |
The story: Q4 was a breakout quarter—sales accelerated, margins expanded sharply (operating profit jumped 159% YoY). But the full year tells a more nuanced tale. Operating profit grew 24% (a genuine achievement in a slow-growth environment), yet net profit declined 1.5%. Why? Exceptional items. The Labour Code impact (₹40.88 Cr provision for enhanced gratuity and leave benefits) hit the quarter and shifted profit into loss territory for the full year.
Remove the Labour Code provision, and FY26 PAT would have been closer to ₹61 Cr—a 13% growth story. Management’s framing emphasizes this. It’s not wrong. But it’s also classic earnings management: exceptional items are always “non-recurring” until they recur. The company faces real provision for a Gabon receivable (₹52.9 Cr outstanding for 3+ years, ₹12.47 Cr provision taken in FY26). That’s not theoretical. That’s loss-making business that hasn’t been written off yet.
On the concall: Management emphasized “steady performance driven by diversified business profile” and noted the glass division now sells 60% to beverages vs. 40% pharma—a deliberate mix shift toward higher margins. The leasing business is now fully occupied (both properties) after previous slack. These are real positives, but they’re neither new nor material enough to justify re-rating the stock.
Section 5: Valuation Discussion: Fair Value Range
Methodology 1: P/E Multiple Method
FY26 EPS: ₹85.92 (reported) Peer P/E band: 11x–18x (sector median 15.2x; Empire’s small-cap diversified status justifies below-median multiple) Fair value range: ₹945 to ₹1,546 per share
Methodology 2: EV/EBITDA Method
FY26 EBITDA: ₹131.6 Cr (PBT ₹60.1 Cr + Interest ₹28.26 Cr + Depreciation ₹16.4 Cr – Labour Code exception, it’s already netted) EV/EBITDA multiple range: 6x–8x (peer range 6.2x–24x; smaller companies trade at lower multiples) Enterprise Value: ₹790 to ₹1,053 Cr Less: Net Debt of ₹52.4 Cr (Borrowings ₹172 Cr – Cash ₹119.6 Cr) Equity Value: ₹738 to ₹1,001 Cr Per share (0.6 Cr shares): ₹1,230 to ₹1,668
Methodology 3: DCF (Simplified)
Assumptions:
- Revenue CAGR next 5 years: 8% (historical 5-year CAGR: 8.3%)
- EBIT margin stabilizing: 12% (FY26: 11.9%)
- Tax rate: 14% (FY26: 14%)
- Terminal growth: 3%
- WACC: 9%
Implied fair value per share: ₹1,100–₹1,200
Fair Value Range: ₹1,050 to ₹1,400 per share
Current price (₹1,007) sits at the lower end. Upside to midpoint: ~18%. Downside risk if revenue growth slows below 5% or margins compress further: ~15%.
Fair Value Disclaimer (Mandatory): This fair value range is for educational purposes only and is not investment advice.
Section 6: What’s Cooking: News, Triggers, Drama
1. Labour Code Impact (₹40.88 Cr provision): The Government of India’s new Labour Codes (effective November 2025) trigger increased gratuity and leave liability. Empire took a one-time provision for past service costs. It’s non-recurring in theory but sets a higher baseline for future years. This is not a red flag—it’s a fact of life for labour-heavy manufacturers. But it does trim reported earnings artificially.
2. Gabon Receivable Debacle: ₹52.9 Cr outstanding from DESNL/OIL, Gabon for 3+ years. ₹40.44 Cr already provided in FY24-25. ₹12.47 Cr fresh provision in FY26. The Board has now decided to fully provide for the outstanding balance—a quiet acknowledgement that this money is gone. It’s a sunk cost, but it’s still a loss.
3. Cost Auditor Appointment: M/s. Vinay Mulay & Co appointed as cost auditor for FY27. Routine, but signals management’s intention to keep costs under scrutiny post-Labour Code changes.
4. Medtech Division Announced: On 13 March 2026, Empire appointed Hemant Kumar Bhardwaj as Divisional CEO of a “Proposed Medtech Division.” This is the first real diversification play in years. Glass pharma bottles → supplying medtech devices. It’s a natural evolution, but it’s also speculative. No financials, no timeline, no clarity. Watch this space.
5. Fully Occupied Leasing Properties: Both office spaces (Lower Parel and Vikhroli) now at 100% occupancy as of August 2025. This is a genuine operational achievement after years of slack. Rent escalation clauses are built in. This is the most stable cash generator the company has.
6. Dividend Acceleration: ₹50 per share (final ₹25 + special ₹25) on a ₹10 face value = 500% payout. The company has ₹119.6 Cr in cash and strong operating cash flow (₹59 Cr in FY26). The double-dip dividend is a signal: management sees no better use for cash than returning it. Either conservative capital allocation or lack of growth opportunities. Probably both.
Section 7: Balance Sheet: The Quiet Asset Accumulator
| Item | FY26 | FY25 | FY24 | Verdict |
|---|---|---|---|---|
| Total Assets | ₹815.1 Cr | ₹750.9 Cr | ₹724 Cr | Growing, but slowly. ₹65 Cr added YoY is mostly real estate WIP and investments. |
| Equity + Reserves | ₹351.5 Cr | ₹338.1 Cr | ₹300.2 Cr | Steady accumulation via retained earnings. Zero external capital raised. |
| Borrowings | ₹172.0 Cr | ₹150.5 Cr | ₹168 Cr | Ticked up YoY, but still manageable. ~78% is fixed deposits (renewals). |
| Net Debt | ₹52.4 Cr | ₹19 Cr | ₹37.6 Cr | Small net debt position. The company has more cash than net borrowing needs. |
Three sarcastic bullets:
• The balance sheet looks like a 126-year-old company that just learned to say no. Assets growing at 8.5%, earnings staying flat—that’s not compound value creation, that’s compound asset hoarding.
• ₹172 Cr in borrowings, 78% of which are fixed deposits. The company isn’t borrowing from banks; it’s borrowing from retail investors at ~6-7% rates. It’s the genteel version of a shadow bank, except it manufactures bottles and rents office space.
• Net debt of ₹52.4 Cr on ₹604 Cr market cap. The company is 91% equity-financed. For a diversified conglomerate, that’s conservative to the point of being cautious. It’s not leverage-risky; it’s growth-starved.
Section 8: Cash Flow: The Sab Number Game Hai
| Year | Operating CF | Investing CF | Financing CF | Free CF | FCF Yield |
|---|---|---|---|---|---|
| FY24 | 74.7 | -15.2 | -52.1 | 59.5 | 9.8% |
| FY25 | 92.4 | 16.8 | -59.2 | 109 | 18% |
| FY26 | 59.0 | -51.3 | -20.3 | 7.7 | 1.3% |
The story: Cash generation from operations is steady (~₹60-90 Cr annually), but it’s lumpy. FY26 saw a sharp drop in operating cash (₹59 Cr from ₹92 Cr in FY25) driven by working capital buildup. Investing cash was negative (₹-51.3 Cr), reflecting capex on the real estate project. Financing cash was used for dividend payments and debt reduction.
Free cash flow collapsed in FY26 (₹7.7 Cr vs ₹109 Cr in FY25) due to the capex surge. This is normal for a real estate project in construction phase, but it signals that near-term dividends are being funded from existing cash, not from organic cash generation.
Wisdom drop: When a diversified company’s free cash flow swings wildly, it often means capital is being misallocated. Empire’s cash is going into a real estate project in Ambernath that contributes 1% to FY26 revenue. Until that project generates returns, the company’s cash conversion story remains cloudy.
Section 9: Ratios: Sexy or Stressy?
| Metric | FY26 | Assessment |
|---|---|---|
| ROE | 15.6% | Respectable, not remarkable. The industry median (ex-IT) is 12%, so Empire is ahead. But 15.6% on a ₹351.5 Cr equity base while earning ₹52.4 Cr is exactly what you’d expect from a slow-growth, cash-generative business. Not a compounding machine. |
| ROCE | 18% | Higher than ROE, implying capital structure benefits. Borrowings are cheap relative to returns. But 18% on ₹523 Cr of invested capital (equity + borrowings) earning ₹94 Cr (EBIT before tax) — the math works, but growth is the constraint, not returns. |
| P/E | 11.7x | Looks cheap vs. sector median of 15.2x. But cheapness reflects lack of growth visibility. At 8% revenue growth and 15% ROE, this is fair value, not a bargain. |
| Debt/Equity | 0.49x | Conservative. The company could borrow more. It chooses not to. That’s either prudence or lack of growth opportunities—probably both. |
| Interest Coverage | 2.13x | Adequate but not comfortable. If earnings dip or rates rise, coverage tightens. The credit rating (CARE A; Stable) is justified. |
| Dividend Yield | 4.96% | On the ₹50 special dividend recommendation, this is elevated. Unsustainable if earnings don’t grow. |
Section 10: P&L Breakdown: Show Me the Money
10-Year Revenue & Profit Narrative (₹ Cr)
| Year | Revenue | EBIT | Net Profit | EBIT Margin | NP Margin |
|---|---|---|---|---|---|
| FY17 | 405 | 67 | 34 | 16.5% | 8.4% |
| FY18 | 473 | 62 | 47 | 13.1% | 9.9% |
| FY19 | 526 | 59 | 44 | 11.2% | 8.4% |
| FY20 | 575 | 75 | 34 | 13% | 5.9% |
| FY21 | 490 | 43 | 13 | 8.8% | 2.7% |
| FY22 | 544 | 59 | 24 | 10.8% | 4.4% |
| FY23 | 682 | 79 | 36 | 11.6% | 5.3% |
| FY24 | 606 | 64 | 37 | 10.5% | 6.1% |
| FY25 | 677 | 70 | 54 | 10.3% | 8% |
| FY26 | 731 | 87 | 52 | 11.9% | 7.1% |
The 10-year arc: A company that peaked in FY18 (₹473 Cr revenue, 14% EBIT margin, ₹47 Cr profit), then stumbled into FY21 (pandemic + lockdown chaos), recovered partially by FY23 (₹682 Cr revenue), and then flatlined at ₹730 Cr by FY26.
Revenue growth from FY17 to FY26: 80% over 9 years = 7.1% CAGR. That’s below inflation + population growth.
Margins are the real story. FY17 had 16.5% EBIT margins. FY26 has 11.9%. This margin compression reflects the deliberate business mix shift: away from high-margin glass pharma bottles (pushed to 40% of glass revenue), toward lower-margin frozen foods and trading (now 43% of revenue). Management chose lower margins for growth. Growth didn’t materialize, but margins stayed compressed. That’s the trap.
Net profit margin has oscillated between 2.7% (FY21 disaster) and 9.9% (FY18 peak). FY26’s 7.1% is respectable but shows earnings leverage to operating profit is weak—working capital, one-offs, and tax volatility create friction.
The punchline: A decade in, Empire is 80% bigger (revenue-wise) but not 80% more profitable. The leverage of scale never materialized. Instead, the company got larger and flatter simultaneously.
Section 11: Peer Comparison
| Company | CMP | P/E | Market Cap (Cr) | ROE % | ROCE % | Pat 12M (Cr) | Sales (Cr) |
|---|---|---|---|---|---|---|---|
| 3M India | 31,995 | 66.51 | 36,068 | 30% | 50% | 542 | 5,090 |
| Godrej Industries | 1,043 | 27.77 | 35,112 | 11.9% | 8.8% | 1,265 | 22,237 |
| DCM Shriram | 1,028 | 18.36 | 16,018 | 11.9% | 11.8% | 872 | 13,538 |
| Balmer Lawrie | 179 | 11.07 | 3,063 | 13.7% | 14.6% | 277 | 2,717 |
| TTK Healthcare | 914 | 18.75 | 1,292 | 6.3% | 8% | 69 | 857 |
| Dhunseri Vent. | 241 | 9.22 | 840 | 2.8% | 4.6% | 91 | 372 |
| Empire Industries | 1,007 | 11.65 | 604 | 15.6% | 18% | 52 | 731 |
| Median (7 cos) | 961 | 15.24 | 2,178 | 11.9% | 11.98% | 184 | 1,914 |
The verdict:
Empire is the smallest in this peer set by market cap (₹604 Cr). That alone explains its lower valuation. But the ratios are interesting. Empire’s 15.6% ROE exceeds the median, and its 18% ROCE is outstanding. Yet the market prices it at 11.65x earnings vs. median 15.24x.
Why? Growth. This list is dominated by companies with scale (Godrej, DCM, 3M) or sector tailwinds (Balmer Lawrie in logistics, TTK in healthcare). Empire is smallest and slowest-growing. The median revenue is ₹1,914 Cr; Empire is ₹731 Cr. Smaller, slower, older.
The real loser here is Dhunseri (P/E 9.22x, 2.8% ROE, 4.6% ROCE). That’s a genuinely broken business. Empire, by comparison, is healthy but stuck. It deserves a re-rating only if it can prove the ₹35-acre Ambernath project works or the medtech division scales.
Section 12: Miscellaneous: Shareholding & Promoters
Shareholding Pattern (as of Mar 2026)
| Category | % |
|---|---|
| Promoters | 72.55% |
| Dileep Malhotra | 27.05% |
| Ranjit Malhotra | 18.59% |
| Randil Trading Company Pvt Ltd | 18.53% |
| Kabir Malhotra | 3.26% |
| Others (Malhotra family trusts) | 5.12% |
| DIIs (LIC ASM) | 5.95% |
| Public | 21.49% |
The Malhotra family has run this company since 1900. Dileep and Ranjit are the current shepherds (27% and 18.6% respectively). The family structure is typical of old Bombay business houses: holding companies, trusts, and PvLtds layered to manage succession and tax. In March 2026, Ushadevi and Satishchandra Malhotra’s holdings (combined 4.89%) got transferred into Dileep and Ranjit’s names—a quiet consolidation play. This suggests generational succession is formalizing.
LIC ASM holds 5.95% (largest institutional shareholder). Public holding is 21.49%—respectable for a small-cap. No pledging. Clean.
Promoter risk assessment: Low. The Malhotras aren’t promoters-on-the-run or financial engineers. They’re old-money industrialists managing legacy assets. But they also have zero urgency to grow. That’s a feature if you’re retired, a bug if you’re a growth-seeking investor.
Section 13: Corporate Governance: Angels or Devils?
The Audit Trail:
Board approved FY26 audited results on 27 May 2026. Statutory auditors (A.T. Jain & Co, FRN 103886W) issued an unqualified opinion. No red flags there.
Credit Rating: CARE A; Stable (reaffirmed August 2025). The rationale: “Steady operating and financial performance” driven by diversified business and improved leasing occupancy. Key sensitivities are to declining cash accruals below ₹40 Cr (red flag) or occupancy falling below 65% (unlikely). The rating doesn’t scream strength, but it’s solid.
Receivable Issue: The ₹52.9 Cr Gabon receivable is the governance elephant. Outstanding 3+ years, partially provided, now fully provided as of FY26. The Board acknowledged it won’t be recovered. This is prudent governance—taking the hit upfront—but it’s also a reminder that Empire conducts business in countries with currency controls and political risk. Lesson: Due diligence in cross-border indenting is an art, not a science.
Labour Code Compliance: The company took a one-time ₹40.88 Cr provision for enhanced gratuity/leave liability. This is governance-correct. Many companies delayed the recognition. Empire didn’t. That’s a positive signal.
No resignations, no pledges, no surprises. This is a well-run, dull company. Which is fine for a 126-year-old business. Drama is for startups.
Section 14: Industry Roast: The Diversified Conglomerate Problem
“Diversified” is what companies call themselves when they’ve lost focus. Empire is diversified: glass, food, real estate, machine tools, office leasing. That’s not a business strategy; that’s a museum of old ideas.
Glass: The container glass industry in India is consolidated around a few large players. Capacity exceeds demand. Margins are perpetually under pressure. Empire’s glass division earns decent returns (55% EBIT margin), but it’s not growing. Why? Because the company already makes 1.9 million bottles per day and the market grows 3-4% annually. Capacity is fine; demand is the ceiling.
Frozen Foods: This is a low-margin, forex-exposed nightmare. Competitors are larger (Godrej, Hindustan Unilever) and have scale advantages. Empire fights for shelf space in 5-star hotels and restaurants—a volatile, unpredictable market. 20% growth sounds great until you realise that 20% is off a small base (₹240+ Cr segment) and margins are razor-thin.
Real Estate: The ₹35-acre Ambernath project has been under development for 15+ years with zero revenue. It’s now in phase VII with 81% units sold. Three phases are 20-45% complete. This is a classic real estate money trap: customer-funded (good), illiquid (bad), execution-dependent (risky). The upcoming Chikoli railway station could be a game-changer. Or it could be a myth. Real estate is never boring; it’s usually disappointing.
Machine Tools: A commoditised, price-competitive segment. Indenting (acting as agent) means Empire takes a margin on someone else’s product. Volume matters; margins don’t. Growth depends on Indian capex cycles. When government or corporates invest, Empire’s agency business hums. When they don’t, it dies. Cyclical, not compounding.
Office Leasing: The only stable, recurring revenue stream. Both properties fully occupied. But it’s also the smallest segment and most vulnerable to disruption. Remote work, co-working spaces, and new commercial real estate could commoditise office leasing. Empire’s properties in Parel and Vikhroli were cutting-edge 20 years ago. Today, they’re old institutional space competing with swanky new developments.
The roast: Empire’s diversification isn’t strategic; it’s accidental. The company owns glass-making capacity, inherited food import relationships, sits on real estate, and rents office space. If any one of these segments boomed, the company would be worth 2-3x more. Instead, all of them are mature, slow-growth, and margin-challenged. Diversification was supposed to spread risk. It’s just spread mediocrity.
Section 15: EduInvesting Verdict
SWOT Summary
| Strengths | Weaknesses |
|---|---|
| 15.6% ROE, 18% ROCE — solid capital efficiency | Revenue growth of 8% YoY is below inflation plus nominal GDP growth; real growth is negative |
| Fully occupied leasing properties with rent escalation | Real estate project (81% sales, 20-45% complete) carries execution risk and ties up capital |
| CARE A rating; stable financial position | Margin compression over decade (16.5% in FY17 to 11.9% in FY26) due to business mix shift |
| Zero pledging; promoter-owned with zero external capital needs | Gabon receivable debacle (₹52.9 Cr written off) signals cross-border execution challenges |
| Opportunities | Threats |
|---|---|
| Medtech division (announced March 2026) could unlock synergies with pharma glass expertise | Glass industry consolidation and capacity surplus limit pricing power |
| Ambernath real estate project execution could unlock ₹50+ Cr NPV if Chikoli railway station project delivers | E-commerce and new commercial buildings reduce occupancy appeal of Parel/Vikhroli legacy properties |
| Frozen foods business growing 20% YoY in a limited total-addressable market | Forex volatility and commodity price fluctuations erode trading margins unpredictably |
| Leasing business at full occupancy creates reinvestment opportunities | Competition from larger companies (Godrej, HUL) in each segment |
The Narrative:
Empire Industries is a century-old company that made money in the 20th century and has been figuring out how to exist in the 21st. It’s not dying—operating cash flow of ₹59 Cr, net debt of ₹52.4 Cr, and a ₹604 Cr market cap suggests a stable, albeit stagnant, business. The balance sheet is fortress-like. The dividend is generous (₹50 per share, a 4.96% yield). The stock is valued fairly (11.65x earnings is not a bargain, but not a trap either).
The issue: No narrative of growth. Glass is mature. Food trading is thin-margin. Real estate is illiquid and long-duration. Office leasing is legacy. The medtech division is speculative. Unless management can prove execution on Ambernath or scale the medtech play, Empire will continue to be what it is—a respectable, dull company that returns cash to shareholders while the business flatlines.
For investors seeking growth, this is not it. For income-focused portfolios or family offices looking for stability, the 4.96% dividend yield and zero financial risk might be appealing. But even for those, the question remains: Would you rather own ₹604 Cr of diversified legacy assets or a single, focused business growing at 15%? Empire asks you to choose the former. Most modern investors disagree.
Closing wisdom: A company’s ability to return cash doesn’t prove its ability to compound wealth. Generosity to shareholders is sometimes a sign of resignation, not confidence. Watch the medtech division. If it scales, the story changes. Until then, Empire remains a value play for the patient, not a growth story for the hungry.